🇺🇸 FDA

Company profile · Sponsor

Entrada

Entrada Therapeutics

TRDA · NYSE pharma BOSTON, MA, USA
Pipeline
4
Drugs
0
Patents
5

Quick answer

Entrada (TRDA) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 5 patents to this profile..

Company facts

Ticker TRDA
Exchange NYSE
Company type pharma
Headquarters BOSTON, MA, USA
SEC CIK 0001689375

Pipeline (4)

Search pipeline →

  1. ENTR-601-44

    Entrada

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  2. ENTR-601-44, SODIUM CHLORIDE

    Entrada

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  3. ENTR-601-45

    Entrada

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  4. SODIUM CHLORIDE, ENTR-601-45

    Entrada

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

Patents (5)

Search patents →

  1. US 11987821

    Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11225506

    Cell penetrating peptides and methods of making and using thereof

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11168310

    Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10815276

    Cell penetrating peptides and methods of making and using thereof

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10626147

    Cell penetrating peptides and methods of making and using thereof

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Entrada?

Entrada (TRDA) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 5 patents to this profile..

What pipeline programs does Entrada sponsor?

We track 4 ClinicalTrials.gov-linked programs for Entrada, including ENTR-601-44 and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Entrada company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.